RE:BAN2401I went back to this review paper at: https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00663-w/tables/3
Reading it again, there are some interesting differences between the aducanumab and BAN2401 clinical trials.
1. BAN2401 was dosed at 10 mg/kg twice per month, whereas aducanumab only once per month
2. The BAN 2401 pH3 trial actually showed 80% decrease in the rate of cognitive decline and 60% for funtion, versus 27% and 22% for aducanumab
3. BAN2401 has a much shorter plasma half-life than aducanumab, and much less brain penetration efficiency (which I expect would reduce product getting to target)
4. BAN2401 was not titrated (stepped up) like aducanumab, leading to faster time to results
So the selectivity argument for PMN310 is likely going to translate to the clinic.
The question is, how does PMN310 compare to BAN2401 in terms of binding affinity to target, as well as bullet point #3 above?